Stock Analysis·← Pickers

TRAX

First Tracks Biotherapeutics Inc

First Tracks Biotherapeutics Inc (TRAX) is currently in a range/mixed trend. RSI is at 78.4 (overbought), with 1/3 trend checks passing.

Price
$36.13
2026-07-16
Trend score
1/3
Range / Mixed
RSI (14)
78.4
Overbought
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

TRAX with MA50 and MA200

36.2431.0125.7820.5515.3204/0604/2905/2606/1807/15
TRAX2026-04-062026-07-15
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$19.43+85.92% vs price
MA200
Distance unavailable
RSI (14)
78.4Overbought zone
MACD Signal
BullishMomentum above signal
Macro Support
Not identifiedNo repeated weekly support zone found
Support Quality
Volume data unavailable
Chart Summary
Trend summary for TRAX

First Tracks Biotherapeutics Inc (TRAX) currently looks more uncertain than directional, with a fairly mixed technical picture. The latest available price is $36.13, and 1 of 3 core trend checks are currently passing. Price is trading above the 50-day moving average by 85.9%.

Momentum and stretch context

TRAX currently has an RSI reading of 78.4, which points to very strong short-term momentum but also a fairly extended setup. Stocks can stay strong for longer than expected, but this kind of reading often tells beginners not to confuse strength with low-risk entry timing.

What traders may watch next

Because TRAX is showing stronger momentum inside a more extended backdrop, the next step is often about timing rather than direction. A stock can keep pushing higher, but many traders will still watch for whether the move stays orderly or starts to look too stretched to offer a comfortable entry.

Company profile

About First Tracks Biotherapeutics Inc

First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.

Sector
Healthcare
Industry
Biotechnology
CEO
Daniel R. Faga
Employees
104
Market cap
$1.26B
Beta
0.00
52-week range
$14.72 – $38.49
Dividend
No
Exchange
NASDAQ
Country
US
IPO date
20 Apr 2026
ISIN
US3371851029
CUSIP
337185102
Company profile data from Financial Modeling Prep. TRAX listed on NASDAQ.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about TRAX

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.

TRAX Stock Analysis: Range/Mixed trend, RSI 78 overbought | MyStockHarbor